A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Conditions
- Metastatic Colorectal Cancer
Interventions
- DRUG: Precemtabart tocentecan
- DRUG: Bevacizumab
- DRUG: Trifluridine/Tipiracil (FTD-TPI)
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators